Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

45.47USD
24 Jul 2014
Price Change (% chg)

$-0.65 (-1.41%)
Prev Close
$46.12
Open
$45.53
Day's High
$45.59
Day's Low
$45.09
Volume
135,527
Avg. Vol
122,482
52-wk High
$48.42
52-wk Low
$32.21

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.98
Market Cap (Mil.): $97,730.07
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.80

Financials

  NVO.N Industry Sector
P/E (TTM): 26.64 36.00 36.40
EPS (TTM): 1.73 -- --
ROI: 69.67 19.00 18.27
ROE: 76.16 19.78 19.15
Search Stocks

Denmark's Novo A/S enters hearing technology sector with Sonion purchase

COPENHAGEN, July 15 - Danish investment company Novo A/S said it bought hearing technology firm Sonion from Swedish private equity firm Altor, entering a market in which Denmark has been a major player for decades.

15 Jul 2014

Novo Nordisk to double revenue within a decade: deputy CEO

COPENHAGEN - Danish drugmaker Novo Nordisk, the world's biggest insulin maker, expects to more than double its annual revenue within a decade, its deputy chief executive Kaare Schultz told Reuters.

25 Jun 2014

Novo Nordisk diabetes drug appears effective for weight loss: study

- Novo Nordisk's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated.

14 Jun 2014

Novo Nordisk diabetes drug appears effective for weight loss -study

June 14 - Novo Nordisk's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated.

14 Jun 2014

Novo Nordisk combination diabetes drug effective after 1 yr-study

June 14 - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza maintained superior blood sugar reduction after one year than either medicine separately, according to data from a late stage trial presented on Saturday.

14 Jun 2014

Novo Nordisk changes strategy in Germany, launches diabetes drug

COPENHAGEN - Danish drugmaker Novo Nordisk, the world's biggest insulin producer, said on Wednesday it had decided to launch its diabetes drug Tresiba in Germany on May 1 after seeing signs of a more favourable pricing situation there.

28 May 2014

Novo Nordisk changes strategy in Germany, launches diabetes drug

COPENHAGEN, May 28 - Danish drugmaker Novo Nordisk , the world's biggest insulin producer, said on Wednesday it had decided to launch its diabetes drug Tresiba in Germany on May 1 after seeing signs of a more favourable pricing situation there.

28 May 2014

Chinese city targets pharma firms in graft crackdown

SHANGHAI, May 27 - China's eastern city of Hangzhou is cracking down on graft in the healthcare sector, according to an internal memo from the local government, putting more pressure on global drugmakers operating in the country.

27 May 2014

Novo presents liraglutide data showing 8 pct weight loss

May 16 - Danish drugmaker Novo Nordisk said results from the largest trial of its experimental obesity treatment liraglutide showed an 8 percent weight loss compared to 2.6 percent with placebo after a year of treatment.

16 May 2014

BRIEF-Novo's NovoEight provides long-term reduction of bleeding

COPENHAGEN, May 12 - Novo Nordisk A/S : * Says has announced new phase 3 interim data for NovoEight, which shows that it provides long-term reduction of bleeding in people with haemophilia A when used as a preventative treatment. * The results were presented at the World Federation of Haemophilia World Congress and support findings from other studies.

12 May 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €77.32 +0.39
Eli Lilly and Co (LLY.N) $64.37 +0.12

Earnings vs. Estimates

Search Stocks